You are here

Article Text

Article menu
Download PDFPDF
Featured editorial
The greying of cardiology: implications for management
  1. Nanette K Wenger
  1. Correspondence to:
    Professor Nanette K Wenger
    Emory University School of Medicine, 49 Jesse Hill Jr Drive, Atlanta, Georgia 30303, USA; nwenger{at}emory.edu

Abstract

“The development of new therapies and devices should reflect the dominant population that will ultimately use them—in the case of cardiovascular therapies and devices, this is exemplified by elderly patients”

http://dx.doi.org/10.1136/hrt.2006.113852

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Research grants/contracts/trial, Steering Committee: Eli Lilly, Astra Zeneca, Pfizer

      Consultantship: Cardiology Consultant, Bristol Myers Squibb; Women’s Advisory Board, CV Therapeutics; Sanofi-Aventis; NitroMed Heart Failure Advisory Board; Leadership Council for Improving Cardiovascular Care (LCIC) Executive Committee, Schering-Plough; GlaxoSmithKline; AstraZeneca AB; Abbott

      Speakers Bureau (CME): Pfizer, Novartis, Merck, Bristol-Myers Squibb, Eli Lilly, NitroMed, CV Therapeutics